NnBU
NnBU
Token: NNBU


Welcome to a Healthy Future.

ICO dates
Start date: 2018-03-26
End date: 2018-04-25

Registrated in: Cyprus

Platform: Ethereum
Type: ERC20

PREMIUM ICO

HARA

Empowering billions by utilizing a global and transparent data exchange.
Ends in 52 days 18 hours
Goal: 17,000,000 USD
Price: 1 HART = 0.059 USD

Dominium

Dominium Blockchain – The one-stop-platform for everything to do with property anywhere in the world!
Ends in 21 days 18 hours
Goal: 17,500,000 USD
Price: 1 DOM = 0.25 EUR
NnBU categories
Health
NnBU whitepaper
Video
NnBU token sale
KYC passing required Yes | Whitelist Yes | Restriction for countries No
Tokens for sale 52,500,000
Price 1 NNBU = 0.32 EUR
Price in PreICO 1 NNBU = 0.20 EUR
Acceppting ETH
NnBU news, social
NnBU search trends in Google
Random whitepaper excerpts

DRAFT VERSION
Index
IMPORTANT NOTICE
3
Forward Looking Statements
5
Details of the Token Sale Events
6
Expected Timetable Of Principal Events
6
Abstract
7
A. The Device
8
A1. What is it?
8
A2. What Happens Next?
12
Roadmap In A Timeframe From May 2018 To May 2025
13
B. The Market
14
C. The Company’s Business Model
16
D. Financial Projections
17
E. The Token
20
F. Proposed Use Of Funds
25
G. Risk Factors
26
H. Corporate Details
30
I. Corporate Finance Advisor’s Letter on the White Paper
31
WHITE PAPER - NNBU HOLDINGS LIMITED
2
...

DRAFT VERSION
IMPORTANT NOTICE
'
This White Paper is not a prospectus.
'
The contents of this White Paper do not constitute or form part of any offer or invitation to
subscribe, issue or sell, or any solicitation of any offer to purchase or subscribe for, any
shares or other securities of NNBU HOLDINGS (‘the Company’) and/or of its subsidiaries in
any jurisdiction.
'
This White Paper constitutes an invitation to prospective purchasers to make an offer to
acquire NnBU Tokens (“Tokens”), which offer the Company may or may not accept. It does
not constitute an offer by the Company to sell Tokens.
'
This White Paper cannot be relied upon in connection with an offer to purchase anything
other than Tokens.
'
The NnBU Tokens (“Tokens”) described in this White Paper will comprise only a contractual
right between the Token Holders and the Company to receive a proportional part of the
Revenues of the Company in accordance with the terms set ou...

DRAFT VERSION
'
NnBU’s product is under development. The Company has not traded and has no operations.
It has no sales or revenues and has made no trading profits or losses in the past.
'
The selling price of each Token has been determined by the Company. The selling price
does not necessarily bear any relationship to the assets, book value, or potential earnings of
the Company or any other recognized criteria of value and must be independently evaluated
by each purchaser of a Token.
'
Prior to deciding whether to invest, each prospective contributor should consider all of the
information contained in this White Paper, especially the matters described in
Section G
entitled “Risk Factors”.
'
To the best of the knowledge and belief of the Directors of the Company, this White Paper
does not contain any untrue statement of a material fact or omit to state any material fact
necessary to make the statements herein, in light of the circumstances under which t...

DRAFT VERSION
Forward Looking Statements
This White Paper contains forward looking statements including, without limitation, statements
containing the words “anticipate”, “believe”, “estimate”, “expect” and similar expressions and
variations of such words, and similar expressions of future or conditional verbs such as “may”,
“could”, “should”, “would”, that identify forward-looking statements, but their absence does not
mean that the statement is not forward-looking. These forward-looking statements are not
guarantees of future performance. Such forward-looking statements are subject to unknown
risks, uncertainties, assumptions and other factors that could cause the financial condition,
actual results, performance or achievements of the Company to differ materially from those
implied by such forward-looking statements. Factors that might affect the Company and cause a
difference include, but are not limited to, those discussed in “Risk Factors”. Given these
unce...

DRAFT VERSION
Details of the Token Sale Events
Minimum contribution amount
Target contribution amount
Total amount of tokens minted
Tokens reserved for the pre-sale event
Tokens reserved for the ICO sale event
Tokens locked up in token reserve
-

8,600,000
-

15,000,000
-
60,000,000 tokens
- 15,000,000 tokens (priced at 0.20 Euro)
- 37,500,000 tokens (priced at 0.32 Euro)
-
7,500,000 tokens
The price per token expressed in Ethereum will vary each day based on the parity Euro –
Ethereum. For the purposes of setting the price per token in Ethereum, each day during the ICO
period (both events) the price will be set at 21:00 CET for contributions to be made on the
following day (00:00 CET to 11:59 CET). The parity will be taken each day at the time mentioned
from the Kraken exchange at kraken.com. As an example, if on March 31 (thus the ICO sale
event price of

0.32) at 21:00 CET the par...

DRAFT VERSION
Abstract
The purpose of this Initial Coin Offering (“ICO”) is for the company NNBU HOLDINGS (derived
from Neo-natal Birth Unit) to raise sufficient funds to i) complete the design of its medical device,
ii) ensure that the Company can prepare an assembly plant for the device once the design is
completed, certified and readied for manufacture, and iii) be able to introduce the device to the
market. The device aims to replicate for a baby born by Caesarean-section some of the physical
stresses undergone by a baby delivered naturally. The Company aims to raise the equivalent of

15,000,000 (Fifteen Million Euros), the Target Contribution, and will issue “passive income”
tokens (a token which entitles the holder to receive payments without having to take any further
action other than those naturally linked to collecting payments) which, in aggregate and
assuming the target contribution is attained, would receive each year a figure equal to 12.5% of
the Company’s sal...

DRAFT VERSION
A. The Device
A1. What is it?
The nature of the problem.
The inventors of the device, Claus Peters and Johannes Schenck,
were inspired to start the development of the medical device when they met in pre-natal classes.
Being both engineers, they started talking about the alternative forms of delivery that were being
explained, and after a lot of investigation and market screening, came up with the idea for the
device. The device aims to replicate for a baby born by Caesarean-section some of the physical
stresses undergone by a baby delivered naturally
1
. Researchers have identified a higher
incidence of a number of medical issues in C-section children over the course of their lives as
compared with children who were born naturally. These issues appear to be immunological in
nature and include asthma, allergy
2
, type 1-diabetes, obesity and celiac disease
3
. The
hypothesis is therefore that the stresses of a natural birth are necessa...

DRAFT VERSION
design has reached a level sufficient for it to be patented. They were joined by Frédéric Vo Van
and together constituted NnBU GmbH, which is now a subsidiary of the Cyprus company, NNBU
HOLDINGS LIMITED.
The conceptual design of the medical device, derived from the patent, is shown below.
The NnBU solution
. The device, whose interior is heated, partially simulates a natural birth by
means of pre-defined or freely definable pressure phases upon freely definable areas of the
baby’s torso. The individual procedural steps during the simulation of environmental conditions
existing in the mother’s uterus and birth canal include the following:
'
The baby’s body will be positioned, face downwards, within the medical device to
support the draining of remaining foetal lung-fluid. The upper removable and
transparent shell will be locked to the lower shell. The baby’s torso will now be in
contact with the pressure-exerting elements. Head, legs and arms are position...

NnBU Roadmap

1
May 2018
Development of the medical device in cooperation with Fraunhofer IPA;
Device certification by DMTpe GmbH;
Global intellectual property protection;
2
May 2018
Development of the medical device in cooperation with Fraunhofer IPA;
Device certification by DMTpe GmbH;
Global intellectual property protection;
3
May 2020
Germany, Austria & Switzerland (DACH) market entry;
4
May 2021
Investors pay-out in Y1;
France & Benelux market entry;
5
November 2021
Brasil & Argentina market entry;
6
March 2022
Mexico market entry;
7
May 2022
US and Canada market entry; Investors pay-out in Y2;
8
July 2022
Other European countries (UK, Italy, Portugal, Spain, Poland, Hungary, Slovakia, Czech Republic) market entry;
9
February 2023
Turkey and Egypt market entry.
10
May 2023
Investors pay-out in Y3;
11
February 2024
China, India and Indonesia market entry.
12
May 2024
Investors pay-out in Y4;
13
May 2025
Investors pay-out in Y5;
Dr Serge Bakoa
Dr Serge Bakoa Attorney At Law

Tina Fotherby
Tina Fotherby Public Relations Advisor

Mike Boutwell
Mike Boutwell Blockchain Technology Advisor

Sidney Perera
Sidney Perera Corporate Finance Advisor

Srecko Velimirovic
Srecko Velimirovic Corporate Finance Advisor

Ben Jafari
Ben Jafari Comply Advantage

Max Pokam
Max Pokam Project Manager

Gustavo Guimarães
Gustavo Guimarães Smart Contract Developer

Andreas Achleithner
Andreas Achleithner Project Advisor

Petra Sacher
Petra Sacher Medical Advisor

Jürgen Haeberle
Jürgen Haeberle CEO/co-founder and partner of DMT GmbH

Gustavo Guimaraes
Gustavo Guimaraes
Full-Stack Engineer
Smart Contract Developer
Solidity Developer / Auditor Consultant
Blockchain/Smart Contract Engineer
Gustavo Guimarães
Gustavo Guimarães
Smart Contract Developer
Lead Ethereum and Smart Contract Architect
Blockchain and Smart Contracts Engineer
Mike Boutwell
Mike Boutwell
Blockchain Technology Advisor
Tina Fotherby
Tina Fotherby
Public Relations Advisor
Famous Publicity | PR
Advisor